| ‘Bombshell’ CDC Study: Kids Who Got Pfizer Vaccine More Likely Than Unvaccinated to Get COVID Infection |
| 160 Plus Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted |
| A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report |
| A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2 |
| A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
| A Review and Autopsy of Two COVID Immunity Studies |
| A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection |
| AFTER ACTION REVIEW OF THE COVID-19 PANDEMIC: The Lessons Learned and a Path Forward |
| Alberta's COVID-19 pandemic response - Alberta COVID-19 Pandemic Data Review Task Force - Final Report |
| An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam |
| Anthony Fauci on C-SPAN’s Washington Journal |
| Anti-SARS-CoV-2 Receptor-Binding Domain Antibody Evolution after mRNA Vaccination |
| Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers |
| Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study |
| Association between vaccinations and clinical manifestations in children with COVID-19 |
| CDC response to Freedom of Information Act Request re. COVID-19 Reinfection and Transmission |
| CDC/IDSA COVID-19 Clinician Call: Update on Variants & Immunity |
| Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG |
| Cellular immunity to SARS-CoV-2 found at six months in non-hospitalised individuals |
| Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 - A Multidisciplinary Perspective |
| Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection |
| Citizen Petition for the Issuance of a Rule Regarding Freedoms for the Convalesced following COVID-19 Disease |
| Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections |
| COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May – November 2021 |
| Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
| Doctors and scientists urge caution in giving Covid jabs to 'low risk' children |
| Dr. Marty Makary: The Greatest Perpetrator Of Misinformation During Covid Was The U.S. Government |
| Duration of immune protection of SARS-CoV-2 natural infection against reinfection |
| Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 |
| Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity |
| Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections |
| Elevated risk of infection with SARS-CoV-2 Beta,Gamma, and Delta variants compared withAlpha variant in vaccinated individuals |
| FAQ about COVID-19 |
| FINAL REPORT: COVID Select Concludes 2-Year Investigation |
| Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context |
| Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital |
| Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
| Immune cells for common cold may recognize SARS-CoV-2 |
| Immune Response to COVID-19 in India through Vaccination and Natural Infection |
| Immunity passports, fundamental rights and public health hazards: a reply to Brown et al. |
| Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals |
| Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection |
| Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals |
| Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees |
| Increasing SARS-CoV2 cases, hospitalizations, and deaths among the vaccinated populations during the Omicron (B.1.1.529) variant surge in UK |
| Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France |
| Large-scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection |
| Lasting immunity found after recovery from COVID-19 |
| Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1) |
| Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2 |
